Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial - CALGB/alliance 170601
E M L Smith, H Pang, C Ye, C Cirrincione, S Fleishman, E D Paskett, T Ahles, L R Bressler, N Le-Lindqwister, C E Fadul, C Loprinzi, C L Shapiro, Alliance for Clinical Trials in Oncology, E M L Smith, H Pang, C Ye, C Cirrincione, S Fleishman, E D Paskett, T Ahles, L R Bressler, N Le-Lindqwister, C E Fadul, C Loprinzi, C L Shapiro, Alliance for Clinical Trials in Oncology
Abstract
Duloxetine is an effective treatment for oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN). However, predictors of duloxetine response have not been adequately explored. The objective of this secondary and exploratory analysis was to identify predictors of duloxetine response in patients with painful oxaliplatin-induced CIPN. Patients (N = 106) with oxaliplatin-induced painful CIPN were randomised to receive duloxetine or placebo. Eligible patients had chronic CIPN pain and an average neuropathic pain score ≥4/10. Duloxetine/placebo dose was 30 mg/day for 7 days, then 60 mg/day for 4 weeks. The Brief Pain Inventory-Short Form and the EORTC QLQ-C30 were used to assess pain and quality of life, respectively. Univariate and multiple logistic regression analyses were performed to identify demographic, physiologic and psychological predictors of duloxetine response. Higher baseline emotional functioning predicted duloxetine response (≥30% reduction in pain; OR 4.036; 95% CI 0.999-16.308; p = 0.050). Based on the results from a multiple logistic regression using patient data from both the duloxetine and placebo treatment arms, duloxetine-treated patients with high emotional functioning are more likely to experience pain reduction (p = 0.026). In patients with painful, oxaliplatin-induced CIPN, emotional functioning may also predict duloxetine response. ClinicalTrials.gov, Identifier NCT00489411.
Keywords: Duloxetine; chemotherapy-induced peripheral neuropathy; oxaliplatin; pain.
© 2015 John Wiley & Sons Ltd.
Source: PubMed